Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment
Abstract Background Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. Methods Expression profiling data were used to determine the possibility and optimal number of ULMS molecular subtypes. Next, c...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-017-3568-y |
id |
doaj-b1803c84e96244bda27e385ed2807cc9 |
---|---|
record_format |
Article |
spelling |
doaj-b1803c84e96244bda27e385ed2807cc92020-11-25T02:34:42ZengBMCBMC Cancer1471-24072017-09-011711810.1186/s12885-017-3568-yDistinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatmentYang An0Shuzhen Wang1Songlin Li2Lulu Zhang3Dayong Wang4Haojie Wang5Shibai Zhu6Wan Zhu7Yongqiang Li8Wenwu Chen9Shaoping Ji10Xiangqian Guo11Department of Biochemistry and Molecular Biology, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan UniversityDepartment of Biochemistry and Molecular Biology, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan UniversityDepartment of Biochemistry and Molecular Biology, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan UniversityDepartment of Biochemistry and Molecular Biology, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Henan UniversityDepartment of Biochemistry and Molecular Biology, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan UniversityDepartment of Orthopedic Surgery, Peking Union Medical College, Chinese Academy of Medical ScienceDepartment of Anesthesia and Perioperative Care, University of CaliforniaDepartment of Biochemistry and Molecular Biology, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan UniversityDepartment of Neurology, The First Affiliated Hospital of Henan UniversityDepartment of Biochemistry and Molecular Biology, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan UniversityDepartment of Biochemistry and Molecular Biology, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan UniversityAbstract Background Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. Methods Expression profiling data were used to determine the possibility and optimal number of ULMS molecular subtypes. Next, clinicopathological characters and molecular pathways were analyzed in each subtype to prospect the clinical applications and progression mechanisms of ULMS. Results Two distinct molecular subtypes of ULMS were defined based on different gene expression signatures. Subtype I ULMS recapitulated low-grade ULMS, the gene expression pattern of which resembled normal smooth muscle cells, characterized by overexpression of smooth muscle function genes such as LMOD1, SLMAP, MYLK, MYH11. In contrast, subtype II ULMS recapitulated high-grade ULMS with higher tumor weight and invasion rate, and was characterized by overexpression of genes involved in the pathway of epithelial to mesenchymal transition and tumorigenesis, such as CDK6, MAPK13 and HOXA1. Conclusions We identified two distinct molecular subtypes of ULMS responding differently to chemotherapy treatment. Our findings provide a better understanding of ULMS intrinsic molecular subtypes, and will potentially facilitate the development of subtype-specific diagnosis biomarkers and therapy strategies for these tumors.http://link.springer.com/article/10.1186/s12885-017-3568-yUterine leiomyosarcomaMolecular subtypeMolecular signatureGene expression patternSubtype-specific treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yang An Shuzhen Wang Songlin Li Lulu Zhang Dayong Wang Haojie Wang Shibai Zhu Wan Zhu Yongqiang Li Wenwu Chen Shaoping Ji Xiangqian Guo |
spellingShingle |
Yang An Shuzhen Wang Songlin Li Lulu Zhang Dayong Wang Haojie Wang Shibai Zhu Wan Zhu Yongqiang Li Wenwu Chen Shaoping Ji Xiangqian Guo Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment BMC Cancer Uterine leiomyosarcoma Molecular subtype Molecular signature Gene expression pattern Subtype-specific treatment |
author_facet |
Yang An Shuzhen Wang Songlin Li Lulu Zhang Dayong Wang Haojie Wang Shibai Zhu Wan Zhu Yongqiang Li Wenwu Chen Shaoping Ji Xiangqian Guo |
author_sort |
Yang An |
title |
Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment |
title_short |
Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment |
title_full |
Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment |
title_fullStr |
Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment |
title_full_unstemmed |
Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment |
title_sort |
distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2017-09-01 |
description |
Abstract Background Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. Methods Expression profiling data were used to determine the possibility and optimal number of ULMS molecular subtypes. Next, clinicopathological characters and molecular pathways were analyzed in each subtype to prospect the clinical applications and progression mechanisms of ULMS. Results Two distinct molecular subtypes of ULMS were defined based on different gene expression signatures. Subtype I ULMS recapitulated low-grade ULMS, the gene expression pattern of which resembled normal smooth muscle cells, characterized by overexpression of smooth muscle function genes such as LMOD1, SLMAP, MYLK, MYH11. In contrast, subtype II ULMS recapitulated high-grade ULMS with higher tumor weight and invasion rate, and was characterized by overexpression of genes involved in the pathway of epithelial to mesenchymal transition and tumorigenesis, such as CDK6, MAPK13 and HOXA1. Conclusions We identified two distinct molecular subtypes of ULMS responding differently to chemotherapy treatment. Our findings provide a better understanding of ULMS intrinsic molecular subtypes, and will potentially facilitate the development of subtype-specific diagnosis biomarkers and therapy strategies for these tumors. |
topic |
Uterine leiomyosarcoma Molecular subtype Molecular signature Gene expression pattern Subtype-specific treatment |
url |
http://link.springer.com/article/10.1186/s12885-017-3568-y |
work_keys_str_mv |
AT yangan distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT shuzhenwang distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT songlinli distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT luluzhang distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT dayongwang distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT haojiewang distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT shibaizhu distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT wanzhu distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT yongqiangli distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT wenwuchen distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT shaopingji distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment AT xiangqianguo distinctmolecularsubtypesofuterineleiomyosarcomaresponddifferentlytochemotherapytreatment |
_version_ |
1724807220558823424 |